Knockout animals manifesting hyperlipidemia

Assignee: Lexicon Pharmaceuticals, Inc.

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,402,730
App. No.: 11/347,838
Granted: Jul 22, 2008
Kind: B1

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Genetically engineered cells and animals are described that incorporate a mutated GHP1 allele. Animals that are homozygous for the mutated GHP1 allele are useful for the production of monoclonal antibodies against GHP1.

Claims (2)

1. A transgenic mouse whose genome comprises a disruption of the GPI-anchored HDL Binding protein 1 (GHP1) gene, wherein said mouse exhibits an increase in serum cholesterol levels when compared to a control mouse.

2. A transgenic mouse according to claim 1 , homozygous for said gene disruption, wherein said mouse lacks any expression of GHP1 protein and exhibits hypertriglyceridemia as compared to a control mouse, and wherein the mouse is able to generate antibodies that selectively bind to GHP1.

Assignments (7)

RELEASE OF SECURITY INTEREST Recorded May 5, 2026

From: OXFORD FINANCE LLC

To: LEXICON PHARMACEUTICALS, INC.; LEXICON PHARMACEUTICALS

Reel/Frame 075545/0601 →

SECURITY INTEREST Recorded May 4, 2026

From: LEXICON PHARMACEUTICALS, INC.; LEXICON PHARMACEUTICALS (NEW JERSEY), INC.; LION ACQUISITION CORPORATION

To: HERCULES CAPITAL, INC., AS AGENT

Reel/Frame 075498/0899 →

SECURITY INTEREST Recorded Mar 17, 2022

From: LEXICON PHARMACEUTICALS, INC.

To: OXFORD FINANCE LLC, AS COLLATERAL AGENT